PerkinElmer Opens new Corporate Headquarters and Technology Center
News May 01, 2007
PerkinElmer, Inc. has celebrated the grand opening of its new corporate headquarters and technology center in Waltham, Massachusetts.
The 115,000 square foot campus includes a research and development facility for PerkinElmer's drug discovery, cellular science and diagnostics businesses. The event also marked PerkinElmer's 60th anniversary as a Massachusetts-based technology company.
"Today we celebrate PerkinElmer's proud history and bright future as an innovator as it continues to pioneer in the areas of predictive diagnostics, personalized medicine, and environmental monitoring," said Gregory L. Summe, Chairman and Chief Executive Officer, PerkinElmer, Inc.
"Our new facility provides us with an ideal environment to create innovative new products that will help our customers improve the quality of life - from the discovery of new drugs to the early detection of disease. More than our products, it is our people that define our success. We recognize the Commonwealth of Massachusetts as an exceptional location for top scientific and business talent, and are proud to begin the next phase of PerkinElmer's growth here in Waltham."
Approximately 100 employees, customers, partners and special guests joined PerkinElmer to mark the occasion, which included a ribbon-cutting ceremony, facility tours and reception. The Company currently employs nearly 600 people in Massachusetts, and has more than 8,500 employees worldwide.
In of organic chemistry, reactions are notoriously difficult to analyze. As a result, reaction data in chemoinformatics has been much less developed than information about single molecules. In a new project, titled CGRtools, researchers solved a number of problems to better handle reaction information. The software library is significantly richer in functionality than all the existing tools.READ MORE
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE